Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraidah, Saudi Arabia; Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, USA.
Epilepsy Behav. 2020 Nov;112:107452. doi: 10.1016/j.yebeh.2020.107452. Epub 2020 Sep 18.
In the United States, access to marijuana and its related products has been outlawed since passing the Controlled Substance Act (CSA) in 1970. Under this act, marijuana is classified as Schedule I substance and is considered to have a high potential for dependency and abuse as well as unaccepted medical use. From that time, multiple states have taken measures to legalize and decriminalize the use of marijuana. In June 2018, Epidiolex® (cannabidiol, CBD) was the first cannabis-derived drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of severe forms of epilepsy, Lennox-Gastaut syndrome, or Dravet syndrome. In December 2018, Farm Bill was significant progress in cannabis-related law by which hemp was removed from the definition of marijuana in the CSA. This paper provides an up-to-date overview of the legal status of cannabis-related aspects, including medical marijuana, home cultivation, patient registration, and hemp-derived CBD from the medical perspective in the United States.
在美国，自 1970 年通过《管制物质法案》（CSA）以来，大麻及其相关产品的使用一直被定为非法。根据该法案，大麻被归类为附表 I 物质，被认为具有高度的依赖和滥用潜力，以及不可接受的医疗用途。从那时起，多个州已经采取措施使大麻合法化和非刑事化。2018 年 6 月，Epidiolex®（大麻二酚，CBD）成为美国食品和药物管理局（FDA）批准的第一种用于治疗严重癫痫、Lennox-Gastaut 综合征或 Dravet 综合征的大麻衍生药物。2018 年 12 月，《农场法案》在大麻相关法律方面取得了重大进展，将大麻从 CSA 中对大麻的定义中删除。本文从医疗角度介绍了美国与大麻相关方面的法律地位的最新概述，包括医用大麻、家庭种植、患者登记和大麻衍生的 CBD。
